skip to content
  1. Home
  2. >
  3. Questions
  4. >
  5. CPH: Would appreciate your analysis of CPH's Q1 results that were released last week. [Cipher Pharmaceuticals Inc.]
You can view 2 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Would appreciate your analysis of CPH's Q1 results that were released last week.
Asked by karl on May 16, 2024
5i Research Answer:

EPS of 20c beat estimates of 10c; revenue of $5.86M beat estimates of $5.04M. EBITDA of $3.57M beat estimates of $3.23M. Licencing revenue rose 55%. EBITDA rose 12.5%. Total revenue rose 20%. Cash is $42M. Results are solid, but more growth is expected in 2026 with a new product launch. International (Sweden) demand has been good. Investors like the future growth and the low valuation here and it is getting more interesting overall, in our view.